Antiplatelet and lipid-lowering therapies for the secondary prevention of cardiovascular disease

Are we doing enough?

Marianne Xhignesse, Patrice Laplante, Andrew M. Grant, Théophile Niyonsenga, Elisabeth Delisle, Nathalie Vanasse, Roch Bernier

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

OBJECTIVE: To evaluate whether current recommendations with respect to the treatment of dyslipidemias and the use of anti-platelet agents are being applied in the secondary prevention of cardiovascular disease in primary care settings. DESIGN: Descriptive study based on data from the FAMUS (FAmily Medicine, Universite de Sherbrooke) primary care register. SETTING AND PARTICIPANTS: Two-hundred and thirty-three physicians participating in the FAMUS project contributed information from nonpregnant patients over 20 years of age consulting for a periodic health examination between 1992 and 1996. INTERVENTIONS: Data from patients in secondary prevention (those with or having had angina, a previous myocardial infarction, bypass surgery, coronary angioplasty or peripheral vascular disease) were extracted and analyzed. MAIN RESULTS: Of the 52,505 patients in the register, 4315 (8%) were identified as being in secondary prevention. Overall, 53% were noted as receiving an antiplatelet agent while 4% were taking warfarin therapy, Only 64% (2780) had a complete lipid profile on record while 38% were being treated with a hypolipidemic agent. In the treated group, only 30% had a low density lipoprotein cholesterol level below 3.0 mmol/L compared with 22% in the untreated group. CONCLUSIONS: A large number of patients identified as being in secondary prevention were not screened for dyslipidemias, and, of those who were, the majority were undertreated according to current recommendations. Antiplatelet agents were more widely prescribed but potentially underused.

Original languageEnglish
Pages (from-to)185-189
Number of pages5
JournalCanadian Journal of Cardiology
Volume15
Issue number2
Publication statusPublished - 1 Feb 1999
Externally publishedYes

Fingerprint

Secondary Prevention
Cardiovascular Diseases
Lipids
Platelet Aggregation Inhibitors
Dyslipidemias
Primary Health Care
Medicine
Hypolipidemic Agents
Peripheral Vascular Diseases
Warfarin
Therapeutics
Angioplasty
LDL Cholesterol
Blood Platelets
Myocardial Infarction
Physicians
Health

Cite this

Xhignesse, M., Laplante, P., Grant, A. M., Niyonsenga, T., Delisle, E., Vanasse, N., & Bernier, R. (1999). Antiplatelet and lipid-lowering therapies for the secondary prevention of cardiovascular disease: Are we doing enough? Canadian Journal of Cardiology, 15(2), 185-189.
Xhignesse, Marianne ; Laplante, Patrice ; Grant, Andrew M. ; Niyonsenga, Théophile ; Delisle, Elisabeth ; Vanasse, Nathalie ; Bernier, Roch. / Antiplatelet and lipid-lowering therapies for the secondary prevention of cardiovascular disease : Are we doing enough?. In: Canadian Journal of Cardiology. 1999 ; Vol. 15, No. 2. pp. 185-189.
@article{22d459d0659543428078bf2722b3f06c,
title = "Antiplatelet and lipid-lowering therapies for the secondary prevention of cardiovascular disease: Are we doing enough?",
abstract = "OBJECTIVE: To evaluate whether current recommendations with respect to the treatment of dyslipidemias and the use of anti-platelet agents are being applied in the secondary prevention of cardiovascular disease in primary care settings. DESIGN: Descriptive study based on data from the FAMUS (FAmily Medicine, Universite de Sherbrooke) primary care register. SETTING AND PARTICIPANTS: Two-hundred and thirty-three physicians participating in the FAMUS project contributed information from nonpregnant patients over 20 years of age consulting for a periodic health examination between 1992 and 1996. INTERVENTIONS: Data from patients in secondary prevention (those with or having had angina, a previous myocardial infarction, bypass surgery, coronary angioplasty or peripheral vascular disease) were extracted and analyzed. MAIN RESULTS: Of the 52,505 patients in the register, 4315 (8{\%}) were identified as being in secondary prevention. Overall, 53{\%} were noted as receiving an antiplatelet agent while 4{\%} were taking warfarin therapy, Only 64{\%} (2780) had a complete lipid profile on record while 38{\%} were being treated with a hypolipidemic agent. In the treated group, only 30{\%} had a low density lipoprotein cholesterol level below 3.0 mmol/L compared with 22{\%} in the untreated group. CONCLUSIONS: A large number of patients identified as being in secondary prevention were not screened for dyslipidemias, and, of those who were, the majority were undertreated according to current recommendations. Antiplatelet agents were more widely prescribed but potentially underused.",
keywords = "Hypercholesterolemia, Lipoproteins, Platelet aggregation inhibitors",
author = "Marianne Xhignesse and Patrice Laplante and Grant, {Andrew M.} and Th{\'e}ophile Niyonsenga and Elisabeth Delisle and Nathalie Vanasse and Roch Bernier",
year = "1999",
month = "2",
day = "1",
language = "English",
volume = "15",
pages = "185--189",
journal = "Canadian Journal of Cardiology",
issn = "0828-282X",
publisher = "Pulsus Group Inc.",
number = "2",

}

Xhignesse, M, Laplante, P, Grant, AM, Niyonsenga, T, Delisle, E, Vanasse, N & Bernier, R 1999, 'Antiplatelet and lipid-lowering therapies for the secondary prevention of cardiovascular disease: Are we doing enough?', Canadian Journal of Cardiology, vol. 15, no. 2, pp. 185-189.

Antiplatelet and lipid-lowering therapies for the secondary prevention of cardiovascular disease : Are we doing enough? / Xhignesse, Marianne; Laplante, Patrice; Grant, Andrew M.; Niyonsenga, Théophile; Delisle, Elisabeth; Vanasse, Nathalie; Bernier, Roch.

In: Canadian Journal of Cardiology, Vol. 15, No. 2, 01.02.1999, p. 185-189.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Antiplatelet and lipid-lowering therapies for the secondary prevention of cardiovascular disease

T2 - Are we doing enough?

AU - Xhignesse, Marianne

AU - Laplante, Patrice

AU - Grant, Andrew M.

AU - Niyonsenga, Théophile

AU - Delisle, Elisabeth

AU - Vanasse, Nathalie

AU - Bernier, Roch

PY - 1999/2/1

Y1 - 1999/2/1

N2 - OBJECTIVE: To evaluate whether current recommendations with respect to the treatment of dyslipidemias and the use of anti-platelet agents are being applied in the secondary prevention of cardiovascular disease in primary care settings. DESIGN: Descriptive study based on data from the FAMUS (FAmily Medicine, Universite de Sherbrooke) primary care register. SETTING AND PARTICIPANTS: Two-hundred and thirty-three physicians participating in the FAMUS project contributed information from nonpregnant patients over 20 years of age consulting for a periodic health examination between 1992 and 1996. INTERVENTIONS: Data from patients in secondary prevention (those with or having had angina, a previous myocardial infarction, bypass surgery, coronary angioplasty or peripheral vascular disease) were extracted and analyzed. MAIN RESULTS: Of the 52,505 patients in the register, 4315 (8%) were identified as being in secondary prevention. Overall, 53% were noted as receiving an antiplatelet agent while 4% were taking warfarin therapy, Only 64% (2780) had a complete lipid profile on record while 38% were being treated with a hypolipidemic agent. In the treated group, only 30% had a low density lipoprotein cholesterol level below 3.0 mmol/L compared with 22% in the untreated group. CONCLUSIONS: A large number of patients identified as being in secondary prevention were not screened for dyslipidemias, and, of those who were, the majority were undertreated according to current recommendations. Antiplatelet agents were more widely prescribed but potentially underused.

AB - OBJECTIVE: To evaluate whether current recommendations with respect to the treatment of dyslipidemias and the use of anti-platelet agents are being applied in the secondary prevention of cardiovascular disease in primary care settings. DESIGN: Descriptive study based on data from the FAMUS (FAmily Medicine, Universite de Sherbrooke) primary care register. SETTING AND PARTICIPANTS: Two-hundred and thirty-three physicians participating in the FAMUS project contributed information from nonpregnant patients over 20 years of age consulting for a periodic health examination between 1992 and 1996. INTERVENTIONS: Data from patients in secondary prevention (those with or having had angina, a previous myocardial infarction, bypass surgery, coronary angioplasty or peripheral vascular disease) were extracted and analyzed. MAIN RESULTS: Of the 52,505 patients in the register, 4315 (8%) were identified as being in secondary prevention. Overall, 53% were noted as receiving an antiplatelet agent while 4% were taking warfarin therapy, Only 64% (2780) had a complete lipid profile on record while 38% were being treated with a hypolipidemic agent. In the treated group, only 30% had a low density lipoprotein cholesterol level below 3.0 mmol/L compared with 22% in the untreated group. CONCLUSIONS: A large number of patients identified as being in secondary prevention were not screened for dyslipidemias, and, of those who were, the majority were undertreated according to current recommendations. Antiplatelet agents were more widely prescribed but potentially underused.

KW - Hypercholesterolemia

KW - Lipoproteins

KW - Platelet aggregation inhibitors

UR - https://www.ncbi.nlm.nih.gov/pubmed/10079778

UR - http://www.scopus.com/inward/record.url?scp=0033041855&partnerID=8YFLogxK

M3 - Article

VL - 15

SP - 185

EP - 189

JO - Canadian Journal of Cardiology

JF - Canadian Journal of Cardiology

SN - 0828-282X

IS - 2

ER -